Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion, Rubicon Team on CTC Applications

NEW YORK (GenomeWeb News) – Fluxion Biosciences today said that it has signed a reagent supply and collaboration agreement with Rubicon Genomics aimed at circulating tumor cell applications.

The South San Francisco, Calif.-based firm said that the alliance will integrate enrichment methods for rare cells using Fluxion's IsoFlux System with Rubicon's NovaPlex sample preparation kits.

Fluxion added that the firms will provide sample-specific products from Rubicon's amplification portfolio to samples processed by Fluxion's IsoFlux System. The samples can then be analyzed using a variety of techniques including next-generation sequencing, microarrays, and PCR-based methods.

Further terms of the alliance were not disclosed.

"The Rubicon protocols are simpler, faster and more robust than the competition, and they also yield superior analytical results on sequencing, array, and PCR platforms," Michael Schwartz, program director at Fluxion, said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.